Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 23611978)

1.

Donor lymphocyte infusion: beauty is in the eye of the beholder.

Bishop MR.

Biol Blood Marrow Transplant. 2013 Jun;19(6):849-50. doi: 10.1016/j.bbmt.2013.04.009. Epub 2013 Apr 20. No abstract available.

3.

Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?

Hamadani M.

Biol Blood Marrow Transplant. 2014 Mar;20(3):292-4. doi: 10.1016/j.bbmt.2013.12.571. Epub 2014 Jan 3. No abstract available.

4.

Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation.

Melenhorst JJ, Tian X, Xu D, Sandler NG, Scheinberg P, Biancotto A, Scheinberg P, McCoy JP Jr, Hensel NF, McIver Z, Douek DC, Barrett AJ.

Haematologica. 2012 Jun;97(6):867-73. doi: 10.3324/haematol.2011.053363. Epub 2011 Dec 1.

5.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
6.

Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis.

Shi-Xia X, Hai-Qin X, Xian-Hua T, Bo F, Xiang-Feng T.

Clin Transplant. 2011 Mar-Apr;25(2):E187-98. doi: 10.1111/j.1399-0012.2010.01361.x. Epub 2010 Nov 23.

PMID:
21092011
7.

Graft-versus-host-disease after double cord blood transplantation: a new look at its characteristics.

Milano F, Delaney C, Storb R.

Biol Blood Marrow Transplant. 2013 Jun;19(6):847-8. doi: 10.1016/j.bbmt.2013.04.006. Epub 2013 Apr 10. No abstract available.

8.

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ.

Bone Marrow Transplant. 2009 Feb;43(4):327-33. doi: 10.1038/bmt.2008.321. Epub 2008 Oct 13.

9.

A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.

Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B, Cornett Farley P, O'Hara W, Flomenberg P, Werner-Wasik M, Brunner J, Mookerjee B, Hyslop T, Weiss M, Flomenberg N.

Blood. 2011 Oct 27;118(17):4732-9. doi: 10.1182/blood-2011-07-365338. Epub 2011 Aug 25.

10.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

11.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C.

Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.

12.

Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Resnick IB, Shapira MY, Slavin S.

Transpl Immunol. 2005 Aug;14(3-4):207-19. Epub 2005 Apr 26. Review.

PMID:
15982565
13.

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.

Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R.

Rev Clin Exp Hematol. 2001 Jun;5(2):135-46. Review.

PMID:
11486652
14.

Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.

Novitzky N, Thomas V, du Toit C.

Biol Blood Marrow Transplant. 2013 Apr;19(4):584-8. doi: 10.1016/j.bbmt.2012.12.017. Epub 2012 Dec 25.

15.

Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.

Shimoni A, Nagler A.

Leuk Lymphoma. 2010 Dec;51(12):2154-6. doi: 10.3109/10428194.2010.532892. No abstract available.

PMID:
21133737
16.
17.

Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?

Ringdén O, Sadeghi B.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1615-7. doi: 10.1016/j.bbmt.2012.09.006. Epub 2012 Sep 27. No abstract available.

18.

Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.

Novitzky N, Thomas V, Hale G, Waldmann H.

Bone Marrow Transplant. 2005 Oct;36(8):675-82.

PMID:
16113675
19.

Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanesi M, Longoni P, Gandola L, Lombardo C, Corradini P.

Blood. 2009 May 7;113(19):4771-9. doi: 10.1182/blood-2008-10-183723. Epub 2009 Feb 11.

20.

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS.

Blood. 2010 Jun 24;115(25):5147-53. doi: 10.1182/blood-2010-01-265413. Epub 2010 Apr 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk